Zelboraf
Non-Small Cell Lung Carcinoma, Erdheim-Chester Disease, Metastatic Melanoma + 1 more
Treatment
4 FDA approvals
4 Active Studies for Zelboraf
Treatment for
Non-Small Cell Lung Carcinoma
What is Zelboraf
Vemurafenib
The Generic name of this drug
Treatment Summary
Vemurafenib is a medication that works by blocking the activity of specific mutated proteins involved in cancer growth. It was developed by Roche and Plexxikon, and approved by the FDA in 2011. It is used to treat certain types of melanoma, and Roche and Genentech have launched a development program for other potential uses.
Zelboraf
is the brand name
Zelboraf Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zelboraf
Vemurafenib
2011
1
Approved as Treatment by the FDA
Vemurafenib, otherwise called Zelboraf, is approved by the FDA for 4 uses including Unresectable Melanoma and Metastatic Melanoma .
Unresectable Melanoma
Metastatic Melanoma
Melanoma
Metastatic Melanoma
Effectiveness
How Zelboraf Affects Patients
The drug vemurafenib works by blocking the BRAF protein, which has been linked to cell growth, proliferation, and metastasis. It has been shown to reduce all markers of BRAF activation, as well as reduce the amount of cytoplasmic phosphorylated ERK and cellular proliferation driven by Ki-67. Studies have also shown that vemurafenib almost completely blocks the MAPK pathway.
How Zelboraf works in the body
Vemurafenib is a drug taken orally that works to prevent cancer growth. It specifically targets mutated BRAF-serine-threonine kinase, blocking downstream processes so that the tumor cannot grow and eventually dies. It is most effective against BRAF V600E mutation and has no effect on melanoma cells with normal BRAF mutations.
When to interrupt dosage
The proposed measure of Zelboraf is contingent upon the identified condition, including Non-Small Cell Lung Carcinoma, Erdheim-Chester Disease and Unresectable Melanoma. The measure of dosage fluctuates as per the technique of delivery (e.g. Tablet or Tablet - Oral) featured in the following table.
Condition
Dosage
Administration
Metastatic Melanoma
240.0 mg,
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Melanoma
240.0 mg,
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Non-Small Cell Lung Carcinoma
240.0 mg,
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Erdheim-Chester Disease
240.0 mg,
, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Warnings
Zelboraf has a single contraindication, so it shouldn't be employed while encountering any of the conditions specified in the below table.
Zelboraf Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Zelboraf.
Common Zelboraf Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Vemurafenib.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Vemurafenib.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Vemurafenib.
Amodiaquine
Major
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amodiaquine.
Artefenomel
Major
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artefenomel.
Zelboraf Toxicity & Overdose Risk
Reports of toxicity suggest that taking too much of this medication could lead to an increased risk of skin cancer or faster growth of existing tumors.
Zelboraf Novel Uses: Which Conditions Have a Clinical Trial Featuring Zelboraf?
127 active trials are examining the effectiveness of Zelboraf in alleviating Metastatic Melanoma, Unresectable Melanoma and Erdheim-Chester Disease.
Condition
Clinical Trials
Trial Phases
Non-Small Cell Lung Carcinoma
0 Actively Recruiting
Metastatic Melanoma
0 Actively Recruiting
Erdheim-Chester Disease
4 Actively Recruiting
Phase 1, Phase 2, Early Phase 1
Melanoma
0 Actively Recruiting
Zelboraf Reviews: What are patients saying about Zelboraf?
5
Patient Review
3/3/2012
Zelboraf for Malignant Melanoma with BRAF V600E Mutation
4
Patient Review
3/6/2019
Zelboraf for Malignant Melanoma with BRAF V600E Mutation
2
Patient Review
12/15/2013
Zelboraf for Malignant Melanoma with BRAF V600E Mutation
Patient Q&A Section about zelboraf
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What protein is targeted by Zelboraf?
"The drug Vemurafenib specifically targets the protein BRAF that has the V600E mutation. By interfering with the abnormal BRAF signals, the growth of the cells is slowed or even stopped."
Answered by AI
What is vemurafenib prescribed for?
"Vemurafenib is used to treat certain types of melanoma (a type of skin cancer) that cannot be treated with surgery, or that has spread to other parts of the body. It is also used to treat a certain type of Erdheim-Chester disease (ECD; a disease that causes an overproduction of a type of white blood cells)."
Answered by AI
How long do you take Zelboraf?
"You should start taking ZELBORAF on the same day you start taking COTELLIC. Take ZELBORAF two times a day with or without food
You should take Cotellic and Zelboraf exactly as your healthcare provider tells you. This includes not changing your dose or stopping taking the medication unless your healthcare provider tells you to. You should take Cotellic once a day for 21 days, followed by 7 days off of the medication. This completes a 28-day treatment cycle. You should start taking Zelboraf on the same day that you start taking Cotellic. You should take Zelboraf two times a day with or without food."
Answered by AI
Is vemurafenib chemotherapy?
"A targeted therapy is a drug that targets the cancer’s genetic changes (mutation).
Zelboraf is a targeted therapy drug that is used to treat cancer by targeting the cancer's genetic changes. The generic name for Zelboraf is vemurafenib."
Answered by AI